Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

DuP-697

COX inhibitor
 
BML-EI358-0005 5 mg 135.00 USD
 
BML-EI358-0025 25 mg 468.00 USD
Do you need bulk/larger quantities?
 
DuP-697 is a highly selective and irreversible inhibitor of cyclooxygenase-2 (COX-2). (COX-2 IC50=10nM, COX-1 IC50=800nM). It is an orally effective anti-inflammatory, analgesic and antipyretic agent which is not ulcerogenic. Inhibition of COX-2 by DuP-697 and other inhibitors exacerbates ischemia-induced myocardial dysfunction in the rabbit. It inhibits angiogenesis and induces apoptosis in human endothelial cells.

Product Specification

Alternative Name:(5-Bromo-2[4-fluorophenyl]-3-[4-methylsulfonyl-phenyl]thiophene)
 
Formula:C17H12BrFO2S2
 
MW:411.3
 
CAS:88149-94-4
 
Purity:≥98% (TLC)
 
Identity:Determined by NMR.
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO (10mg/ml) or 100% ethanol (5mg/ml).
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Regulatory Status:RUO - Research Use Only
 
bml-ei358
Please mouse over
bml-ei358

Product Literature References

Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697): A. Churchman, et al.; Eur. J. Pharmacol. 573, 176 (2007), Abstract;
Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit: G. Rossoni, et al.; Br. J. Pharmacol. 135, 1540 (2002), Abstract;
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase: R.A. Copeland, et al.; PNAS USA 91, 11202 (1994), Abstract;
Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor: K.R. Gans, et al.; J. Pharmacol. Exp. Ther. 254, 180 (1990), Abstract;

Related Literature

Brochures
Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2020 Enzo Life Sciences, Inc.,